Brief: Calliditas Therapeutics, Viatris Enter License Agreement
13/12/2022 07:30
Dec 13 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* CALLIDITAS THERAPEUTICS AND VIATRIS ENTER LICENSE
AGREEMENT TO
REGISTER AND COMMERCIALIZE A SPECIALTY THERAPY FOR IGA
NEPHROPATHY IN JAPAN
* LICENSE AGREEMENT IS WORTH UP TO $100 MILLION IN UPFRONT
PAYMENTS AND MILESTONE PAYMENTS
Source text for Eikon: ID:nWkry4ZH9
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations